Arcutis Biotherapeutics Ownership

ARQT Stock

USD 10.14 0.10 0.98%

Arcutis Biotherapeutics holds a total of 117.05 Million outstanding shares. The majority of Arcutis Biotherapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Arcutis Biotherapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Arcutis Biotherapeutics. Please pay attention to any change in the institutional holdings of Arcutis Biotherapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Shares in Circulation

First Issued

2018-12-31

Previous Quarter

123.5 M

Current Value

124.3 M

Avarage Shares Outstanding

54 M

Quarterly Volatility

31.2 M

Covid

Some institutional investors establish a significant position in stocks such as Arcutis Biotherapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Arcutis Biotherapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Dividends Paid is likely to drop to about 107.3 M in 2024. Dividend Paid And Capex Coverage Ratio is likely to gain to -548.37 in 2024. Common Stock Shares Outstanding is likely to drop to about 44.6 M in 2024. Net Loss is likely to gain to about (266.3 M) in 2024.

Market Cap Enterprise Value

Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arcutis Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.

For more information on how to buy Arcutis Stock please use our How to Invest in Arcutis Biotherapeutics guide.

Arcutis Stock Ownership Analysis

About 98.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.67. Arcutis Biotherapeutics had not issued any dividends in recent years. Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Arcutis Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 147 people. For more info on Arcutis Biotherapeutics please contact Todd MA at 805 418 5006 or go to https://www.arcutis.com.

Besides selling stocks to institutional investors, Arcutis Biotherapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Arcutis Biotherapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Arcutis Biotherapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Arcutis Biotherapeutics Quarterly Liabilities And Stockholders Equity

437.35 Million

Arcutis Biotherapeutics Insider Trades History

Roughly 2.0% of Arcutis Biotherapeutics are currently held by insiders. Unlike Arcutis Biotherapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Arcutis Biotherapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Arcutis Biotherapeutics' insider trades

Covid

Arcutis Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Arcutis Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arcutis Biotherapeutics backward and forwards among themselves. Arcutis Biotherapeutics' institutional investor refers to the entity that pools money to purchase Arcutis Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
Cormorant Asset Management, Llc	2024-06-30	2.5 M
Geode Capital Management, Llc	2024-06-30	2.4 M
Ensign Peak Advisors Inc	2024-06-30	2.1 M
Pivotal Bioventure Partners Investment Advisor Llc	2024-06-30	2 M
Deutsche Bank Ag	2024-06-30	1.9 M
Stempoint Capital Lp	2024-09-30	1.8 M
Gw&k Investment Management, Llc	2024-09-30	1.6 M
American Century Companies Inc	2024-09-30	1.5 M
Perceptive Advisors Llc	2024-09-30	1.4 M
Jennison Associates Llc	2024-09-30	11.7 M
Suvretta Capital Management, Llc	2024-06-30	10 M

Note, although Arcutis Biotherapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Arcutis Biotherapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arcutis Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arcutis Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arcutis Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Matsuda Masaru few days ago Acquisition by Matsuda Masaru of 4875 shares of Arcutis Biotherapeutics subject to Rule 16b-3
		Burnett Patrick six days ago Disposition of 100 shares by Burnett Patrick of Arcutis Biotherapeutics at 10.03 subject to Rule 16b-3
		Welgus Howard G. over two weeks ago Disposition of 10000 shares by Welgus Howard G. of Arcutis Biotherapeutics at 8.6541 subject to Rule 16b-3
		Edwards Larry Todd over a month ago Disposition of 3725 shares by Edwards Larry Todd of Arcutis Biotherapeutics at 10.0122 subject to Rule 16b-3
		Welgus Howard G. over a month ago Disposition of 10000 shares by Welgus Howard G. of Arcutis Biotherapeutics at 9.2616 subject to Rule 16b-3
		David Topper over two months ago Acquisition by David Topper of 60000 shares of Arcutis Biotherapeutics subject to Rule 16b-3
		Leonard Keith R over two months ago Acquisition by Leonard Keith R of 27052 shares of Arcutis Biotherapeutics at 8.63 subject to Rule 16b-3
		Welgus Howard G. over two months ago Disposition of 10000 shares by Welgus Howard G. of Arcutis Biotherapeutics at 10.7695 subject to Rule 16b-3
		Welgus Howard G. over three months ago Disposition of 5681 shares by Welgus Howard G. of Arcutis Biotherapeutics at 1.6806 subject to Rule 16b-3
		Welgus Howard G. over three months ago Disposition of 6458 shares by Welgus Howard G. of Arcutis Biotherapeutics at 1.6806 subject to Rule 16b-3
		Burnett Patrick over three months ago Disposition of 23000 shares by Burnett Patrick of Arcutis Biotherapeutics at 8.753 subject to Rule 16b-3
		Matsuda Masaru over three months ago Acquisition by Matsuda Masaru of 4875 shares of Arcutis Biotherapeutics subject to Rule 16b-3

Arcutis Biotherapeutics Outstanding Bonds

Arcutis Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Arcutis Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Arcutis bonds can be classified according to their maturity, which is the date when Arcutis Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	Boeing Co 2196 Corp Bond US097023DG73	View
	HSBC Holdings PLC Corp Bond US404280DR76	View
	US039653AA89 Corp Bond US039653AA89	View
	Ardagh Holdings USA Corp Bond US03969AAP57	View
	Ardagh Holdings USA Corp Bond US03969AAN00	View
	Ardagh Packaging Finance Corp Bond US03969AAR14	View
	US03969YAA64 Corp Bond US03969YAA64	View
	US03969YAB48 Corp Bond US03969YAB48	View

View All Arcutis Biotherapeutics Corporate Bonds

Arcutis Biotherapeutics Corporate Filings

F4	19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify
13A	14th of November 2024 An amended filing to the original Schedule 13G	View Verify
8K	14th of August 2024 Report filed with the SEC to announce major events that shareholders should know about	View Verify
	24th of July 2024 Other Reports	View Verify

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arcutis Stock Analysis

When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC